Advertisement
AXON vs PDSB
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. PDS Biotechnology (PDSB) Stock Comparison
Key Takeaways
- AXON is a profitable, fast-growing public safety technology platform, while PDSB is a clinical-stage biotech with no product revenue and ongoing cash-burn risk.
- AXON has delivered ten consecutive quarters of 30%+ revenue growth, supported by recurring software revenue and a growing counter-drone business, even as its share price has pulled back from 2025 highs.
- PDSB has seen sharp, event-driven swings on financing and clinical-trial headlines, reflecting high volatility and a heavy reliance on external capital.
- Tickeron AI Verdict: AXON is the favored ticker of the two, based on stronger trend consistency, profitability, recurring revenue, and relative market positioning.
- For more detail on each company's developments and daily price action, explore AXON Major News and AXON Today's Price Move, as well as PDSB Major News and PDSB Today's Price Move.
- To see how automated systems are applying these signals in real time, explore the curated Trending AI Robots page.
Introduction
Comparing AXON and PDSB is, in many ways, a study in contrast. One is an established, revenue-generating public safety technology leader; the other is a pre-revenue clinical-stage immunotherapy developer whose fortunes hinge on trial data and financing. This stock comparison is most relevant to investors weighing growth-stage quality against speculative biotech opportunity, and to traders seeking to understand how relative performance, momentum, and risk differ across two very distinct market profiles. By examining business models, recent momentum, catalysts, and market positioning side by side, readers can better assess which profile aligns with their own objectives and risk tolerance.
AXON Overview and Recent Performance
AXON, formerly TASER International, is Axon Enterprise, a public safety technology company based in Scottsdale, Arizona. The company supplies conducted electrical weapons (Tasers), body-worn and in-car cameras, drones, virtual-reality training, and a cloud-based software and evidence-management platform for law enforcement, corrections, federal, and enterprise customers.
In recent quarters, the underlying business has remained strong. Revenue grew roughly 35% year over year in its most recent reported quarter, marking the tenth consecutive quarter of growth above 30%. Software and services revenue advanced at a similar pace, annual recurring revenue (ARR) rose about 39%, and net revenue retention exceeded 125%, signaling that existing customers continue to expand their spending. The counter-drone segment, added through the acquisition of Dedrone, has scaled quickly and surpassed $100 million in quarterly revenue.
Despite this operational momentum, the stock has been volatile. After reaching an all-time high in mid-2025, shares pulled back sharply during the broader software-sector selloff and on concerns about margin compression, rising inventory, and a convertible notes offering. The result has been a notable decline from peak levels even as analysts have largely maintained constructive long-term views. This divergence between fundamentals and price action has shaped recent sentiment.
PDSB Overview and Recent Performance
PDSB is PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies based on its Versamune platform. Its lead candidates include PDS0101 for HPV16-positive cancers and PDS0301 for advanced solid tumors such as colorectal cancer with liver metastases. The company generates no meaningful product revenue and funds operations primarily through equity raises and partnerships.
Recent months have brought substantial volatility. The company announced a restructuring affecting roughly a third of its workforce as it refocused capital toward the broader PDS0301 program while seeking to preserve PDS0101 through partnerships. A financing led by Nant Capital, which placed Patrick Soon-Shiong on the board, provided capital and was interpreted by the market as a strategic endorsement, driving a sharp short-term rally. Registration statements and follow-on offering activity have, however, highlighted ongoing dilution and funding risk.
The share price has traded within a wide range and remains far below levels seen several years ago, with performance largely driven by individual clinical and financing announcements rather than steady operating progress. This event-driven profile makes PDSB's relative performance inherently less predictable than that of a diversified revenue-generating company.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that monitor and trade thousands of different tickers, each running its own strategy, timeframe, risk profile, and performance record. Because not every bot suits every market environment, Tickeron maintains a curated Trending AI Robots section that highlights the bots currently best aligned with prevailing conditions. These bots differ in trading style—ranging from short-term swing and intraday approaches to longer-horizon trend strategies—and in the baskets of tickers they follow, giving traders the ability to match an automated system to their own objectives. Exploring the Trending AI Robots page is a practical way to see how data-driven signals are being applied to stocks like those in this comparison.
Head-to-Head Comparison
The two companies occupy fundamentally different positions across nearly every comparison dimension.
- Business model: AXON combines hardware and recurring software revenue with a sticky installed base and a large contracted backlog. PDSB depends on clinical development milestones, regulatory outcomes, and external financing.
- Growth drivers: AXON's growth is fueled by Taser 10 adoption, body cameras, AI software tools, and counter-drone expansion. PDSB's growth potential rests on trial readouts and eventual regulatory approval of its immunotherapy candidates.
- Recent momentum: AXON has shown consistent operational growth even as its stock corrected from elevated valuations. PDSB has shown sharp, catalyst-driven spikes and declines with no underlying revenue base to anchor valuation.
- Risk factors: AXON faces valuation sensitivity, margin pressure from newer products, and execution risk in scaling new businesses. PDSB faces cash-runway constraints, dilution, and binary clinical and regulatory risk.
- Sector exposure and sentiment: AXON sits at the intersection of public safety, hardware, and software, with broad institutional coverage. PDSB is a small-cap oncology developer where sentiment shifts quickly on single headlines.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, recurring revenue, and relative positioning, Tickeron's AI would likely favor AXON over PDSB in the current environment. AXON offers a more stable, diversified business with durable recurring revenue and a large contracted backlog, which generally supports a more consistent trend profile. PDSB, while capable of sharp catalyst-driven moves, carries materially higher funding, dilution, and clinical risk with no current product revenue. This assessment reflects a probabilistic comparison of stability and momentum rather than a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and PDSB is a Hold.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
PDSB's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | PDSB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 34 | |
P/E GROWTH RATING 1..100 | 80 | 96 | |
SEASONALITY SCORE 1..100 | 43 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PDSB's Valuation (6) in the Pharmaceuticals Major industry is significantly better than the same rating for AXON (90) in the Biotechnology industry. This means that PDSB’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to PDSB’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to PDSB’s over the last 12 months.
PDSB's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as AXON (65) in the Biotechnology industry. This means that PDSB’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (80) in the Biotechnology industry is in the same range as PDSB (96) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to PDSB’s over the last 12 months.
| AXON | PDSB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| Advances ODDS (%) | 16 days ago 74% | 14 days ago 82% |
| Declines ODDS (%) | 2 days ago 70% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while PDSB’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- PDSB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while PDSB’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- PDSB’s TA Score: 4 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -25.64% price change this week, while PDSB (@Biotechnology) price change was -26.95% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.08%. For the same industry, the average monthly price growth was -0.97%, and the average quarterly price growth was -12.77%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
PDSB is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Aerospace & Defense (+5.08% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PDSB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To PDSB | 1D Price Change % | ||
|---|---|---|---|---|
| PDSB | 100% | -0.97% | ||
| AXON - PDSB | 43% Loosely correlated | +4.26% | ||
| PRAX - PDSB | 35% Loosely correlated | +2.55% | ||
| VCYT - PDSB | 35% Loosely correlated | +4.36% | ||
| ARRY - PDSB | 35% Loosely correlated | +9.94% | ||
| ATNM - PDSB | 34% Loosely correlated | +1.27% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LCLG | 69.42 | 1.15 | +1.69% |
| Logan Capital Large Cap Growth ETF (LCLG) | |||
| QVML | 45.21 | 0.47 | +1.06% |
| Invesco S&P 500 QVM Multi-factor ETF (QVML) | |||
| EFR | 10.27 | 0.02 | +0.20% |
| Eaton Vance Senior Floating-Rate Fund | |||
| NRSH | 26.82 | N/A | N/A |
| Aztlan North America Nearshoring Stock Selection ETF (NRSH) | |||
| SIJ | 18.02 | -0.47 | -2.52% |
| ProShares UltraShort Industrials (SIJ) | |||